Numakunai

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma4 trials
• Endometrial cancer3 trials
• Asthma1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Head and neck cancer1 trial

Phase

• Phase 37 trials
• Phase 23 trials

Status

• Recruiting4 trials
• Active, not recruiting3 trials
• Completed3 trials

Lead sponsor

• GlaxoSmithKline10 trials

Running trials

• Recruiting

  A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

  NCT07684599· Phase 3· GlaxoSmithKline· Source

  Contact: Tsukasa Baba (principal investigator)

• Recruiting

  A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

  NCT07286331· Phase 3· GlaxoSmithKline· Source

  Contact: Tsukasa Baba (principal investigator)

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

  NCT07227311· Phase 2· GlaxoSmithKline· Source

  Contact: Shigeki Ito (principal investigator)

• Recruiting

  A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  NCT06679101· Phase 3· GlaxoSmithKline· Source

  Contact: Shigeki Ito (principal investigator)

• Active, not recruiting

  A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

  NCT06317311· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

  NCT06956170· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

  NCT04484623· Phase 3· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Endometrial cancer2 recruiting
• Multiple myeloma2 recruiting

Closed trials

• Recruiting

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· Phase 3· GlaxoSmithKline· Source

• Completed

  Phase 2b Study of GSK4532990 in Adults With NASH

  NCT05583344· Phase 2· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source